The Effectiveness of Elbasir/Grazoprevir in Hepatitis C Patients with Stage 5 Chronic Kidney Disease (CKD)
),
(1) Division of Gastroentero-hepatology, Department of Internal Medicine, Faculty of Medicine-Universitas Brawijaya/Dr. Saiful Anwar General Hospital
Corresponding Author
Abstract
ABSTRACT
Introduction: Treatment of hepatitis C in end stage renal disease patients still a clinical challenge. Elbasvir/grazoprevir is a type of direct acting antiviral (DAA) drug used in treatment of Hepatitis C virus patients with renal disease. However, research on effectiveness of elbasvir/grazoprevir in hepatitis c virus patients with stage 5 chronic kidney disease (CKD) was limited. Therefore, this study aims to describe the effectiveness of elbasvir/grazoprevir on hepatitis C patients with stage 5 chronic kidney disease (CKD).
Method: This research using analytic observational design with cross-sectional study approach. The effectiveness of elbasvir/grazoprevir in hepatitis C patients with stage 5 chronic kidney disease (CKD) were evaluated the viral load, SVR12, and kidney function. Data were obtained from medical records of hepatitis C patients at Hepatology Outpatient Clinic dr. Saiful Anwar hospital from January 1st 2021 until December 31st 2022. Data analysis used the chi-square test, paired t test, and the Wilcoxon test with a significance level of p<0.05 and 95% confidence level.
Results: This study obtained 52 respondents. Most of the patients after treatment elbasvir/grazoprevir had an SVR12 value of 94.23%. Creatinine levels significant increase from 122±40 mg/dl to 133.05±36.12 mg/dl (p=0,032). Urea levels significantly different from 12±3 mg/dl to 12.18±3.56 mg/dl (p=0,446).
Conclusion: Elbasvir/grazoprevir was effective to treat hepatitis C patients with stage 5 CKD.
Keywords: Hepatitis C, stage 5 CKD, effectiveness, elbasvir/grazoprevir
Keywords
References
REFERENCES
Jafri, S. M., & Gordon, S. C. Epidemiology of Hepatitis C. Clinical liver disease. 2018;12(5):140–142. https://doi.org/10.1002/cld.783
Muljono D. Epidemiology of Hepatitis B and C in Republic of Indonesia. Euroasian journal of hepato-gastroenterology. 2017;7(1):55–59. https://doi.org/10.5005/jp-journals-l0018-1212
Azmi, A. N., Tan, S. S., & Mohamed, R. Hepatitis C and kidney disease: An overview and approach to management. World journal of hepatology. 2015;7(1):78–92. https://doi.org/10.4254/wjh.v7.i1.78
Ko, S.Y., and Choe, W. H. Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals. Clinical and Molecular Hepatology. 2018;24:351-357. https://doi.org/10.3350/cmh.2017.0063
Khan, M. U., Mahmoud, M. I., & Butt, A. A. Hepatitis c virus and chronic kidney disease. Expert review of gastroenterology & hepatology. 2020;14(7):579–590. https://doi.org/10.1080/17474124.2020.1776111
Bell, A. M., Wagner, J. L., Barber, K. E., & Stover, K. R. Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C. International journal of hepatology. 2016;3852126. https://doi.org/10.1155/2016/3852126
Jacobson, I. M., Poordad, F., Firpi-Morell, R., Everson, G. T., Verna, E. C., Bhanja, S., Hwang, P., Caro, L., Robertson, M., Charles, E. D., & Platt, H. Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT Study. Clinical and translational gastroenterology. 2019;10(4):e00007. https://doi.org/10.14309/ctg.0000000000000007
Papudesu, C., Kottilil, S., & Bagchi, S. Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection. Hepatology international. 2017;11(2):152–160. https://doi.org/10.1007/s12072-016-9761-2
Lin, C. P., Liang, P. C., Huang, C. I., Yeh, M. L., Hsu, P. Y., Hsu, C. T., Wei, Y. J., Liu, T. W., Hsieh, M. Y., Hou, N. J., Jang, T. Y., Lin, Y. H., Wang, C. W., Lin, Z. Y., Chen, S. C., Huang, C. F., Huang, J. F., Dai, C. Y., Chuang, W. L., & Yu, M. L. Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals. PloS one. 2021;16(2):e0245479. https://doi.org/10.1371/journal.pone.0245479
Zhu, Y., & Chen, S. Antiviral treatment of hepatitis C virus infection and factors affecting efficacy. World journal of gastroenterology. 2013;19(47):8963–8973. https://doi.org/10.3748/wjg.v19.i47.8963
Chuang, W. L., & Yu, M. L. Host factors determining the efficacy of hepatitis C treatment. Journal of gastroenterology. 2013;48(1):22–30. https://doi.org/10.1007/s00535-012-0669-x
Choi, D. T., Puenpatom, A., Yu, X., Erickson, K. F., Kanwal, F., El-Serag, H. B., & Kramer, J. R. Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population. Antiviral research. 2020;174:104698. https://doi.org/10.1016/j.antiviral.2019.104698
Chen, J., Li, Y., Li, G., & Lei, P. Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient. Renal failure. 2020;42(1):377–380. https://doi.org/10.1080/0886022X.2020.1753073
Atsukawa, M., Tsubota, A., Toyoda, H., Takaguchi, K., Kondo, C., Okubo, T., Hiraoka, et al. Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study. Journal of gastroenterology and hepatology. 2019;34(2):364–369. https://doi.org/10.1111/jgh.14447
Article Metrics
Abstract View
: 305 times
Download : 172 times
DOI: 10.24871/2522024302
Refbacks
- There are currently no refbacks.
